跨神经治疗公司任命中枢神经系统药物开发专家马克·A·德米特拉克博士为首席研发官-动脉网

Transneural Therapeutics Appoints CNS Drug Development Expert, Mark A. Demitrack, MD, as Chief Research and Development Officer

CISION 等信源发布 2025-04-30 01:10



可切换为仅中文







Accomplished physician-scientist brings more than 30 years of industry leadership experience and CNS drug development expertise.

资深医生科学家拥有超过30年的行业领导经验和中枢神经系统药物开发专业知识。

SEATTLE

西雅图

，

April 29, 2025

2025年4月29日

/PRNewswire/ --

Transneural Therapeutics, Inc.

跨神经治疗公司

(Transneural), a preclinical-stage biotechnology company aiming to transform the treatment of neuropsychiatric and neurodegenerative diseases with novel neuroplastogens, announced the appointment of

（Transneural），一家处于临床前阶段的生物技术公司，致力于通过新型神经塑性因子彻底改变神经精神疾病和神经退行性疾病的治疗，宣布任命

Mark A. Demitrack

马克·A·德米特拉克

, MD, as Chief Research and Development Officer.

，医学博士，担任首席研发官。

继续阅读

Dr. Mark A Demitrack, MD is a highly accomplished leader with unparalleled scientific and clinical development expertise

马克·A·德米特拉克博士，医学博士，是一位成就卓著的领导者，拥有无与伦比的科学和临床开发专业知识。

Post this

发布这个

Transneural Therapeutics has appointed Dr. Mark A. Demitrack, MD as Chief Research and Development Officer.

Transneural Therapeutics 任命 Mark A. Demitrack 医学博士为首席研发官。

'Mark is a highly accomplished leader with unparalleled scientific and clinical development expertise specific to neuropsychiatry,' said

“马克是一位成就卓著的领导者，在神经精神病学领域拥有无与伦比的科学和临床开发专业知识，”

Charmaine Lykins

查梅因·莱金斯

, Chief Executive Officer of Transneural Therapeutics. 'I am excited to welcome Mark to the team. He has a comprehensive command of all phases of drug development and a track record that includes multiple drug approvals. Mark's leadership will be invaluable to our efforts to progress our

Transneural Therapeutics首席执行官表示：“我非常欢迎马克加入团队。他全面掌握了药物开发的各个阶段，并拥有包括多项药物批准在内的出色业绩记录。马克的领导将对我们推动发展起到不可估量的作用。

pipeline assets

管道资产

, including the development of TN-001 for depression and PTSD.'

`, 包括开发用于治疗抑郁症和创伤后应激障碍的TN-001。'

Dr. Demitrack is an accomplished, internationally recognized neuropsychiatrist with deep expertise in innovative clinical research and strategic business planning. His over 30 years of industry experience includes Chief Medical Officer roles at Trevena and Neuronetics, where he led the clinical development program and successful launch of the NeuroStar TMS Therapy System for treatment resistant major depression. Dr.

Demitrack博士是一位杰出的、国际知名的神经精神病学家，在创新临床研究和战略业务规划方面具有深厚的专业知识。他拥有超过30年的行业经验，曾担任Trevena和Neuronetics的首席医学官，领导了针对难治性重度抑郁症的NeuroStar TMS治疗系统的临床开发计划并成功上市。

Demitrack also served as Medical Director of the New Antidepressant Team at Lilly where he led the development and original NDA submission for the antidepressant, duloxetine (Cymbalta)..

Demitrack 还担任了礼来公司新抗抑郁药团队的医学主任，他领导了抗抑郁药度洛西汀（Cymbalta）的开发以及最初的 NDA 申请工作。

'It's an exciting time to join Transneural as we advance our lead candidate, TN-001, a novel therapeutic that could provide meaningful relief to people living with MDD and PTSD,' said

“在我们推进主要候选药物TN-001时加入Transneural是一个激动人心的时刻，这是一种新型疗法，可能为生活中的重度抑郁症和创伤后应激障碍患者带来有意义的缓解，”

Mark A. Demitrack

马克·A·德米特拉克

, MD, Chief Research and Development Officer of Transneural Therapeutics. 'I look forward to building our research and development organization and partnering with an experienced team of neuroscience leaders focused on bringing new and potentially better treatment options to people living with these debilitating conditions.'.

医学博士，Transneural Therapeutics公司的首席研发官。“我期待着建立我们的研发组织，并与一支专注于为患有这些衰弱症状的人们带来新的、可能更好的治疗选择的神经科学领导团队合作。”

Dr. Demitrack was a faculty member of the Department of Psychiatry at the

德米特拉克博士是精神病学系的教员

University of Michigan

密歇根大学

Medical School, where he received federal grant funding in clinical research investigations studying the neuroendocrine pathophysiology of mood and related disorders. He has published over 100 articles, book chapters and reviews and is a Fellow of the American Psychiatric Association, as well as a Member of the American College of Neuropsychopharmacology..

医学院，他在那里获得了联邦拨款资助，用于临床研究调查，研究情绪及相关障碍的神经内分泌病理生理学。他发表了100多篇文章、书籍章节和评论，并且是美国精神病学协会的会员，以及美国神经精神药理学院的成员。

Dr. Demitrack received a BA in Physics from

德米特拉克博士获得了物理学学士学位

Columbia University

哥伦比亚大学

, and his MD from the Robert Wood Johnson Medical School. He completed psychiatry residency training at UCSF and received research fellowship training at the NIMH.

，并在罗伯特·伍德·约翰逊医学院获得医学博士学位。他在加州大学旧金山分校完成了精神病学住院医师培训，并在国家精神卫生研究所接受了研究奖学金培训。

About Transneural

关于 Transneural

Transneural is a preclinical-stage biotechnology company transforming the treatment of neuropsychiatric diseases with novel neuroplastogens. In development for MDD and PTSD, Transneural's lead asset, TN-001, is a dual 5-HT

Transneural是一家处于临床前阶段的生物技术公司，通过新型神经塑性因子革新神经精神疾病的治疗。该公司正在开发用于治疗重度抑郁症（MDD）和创伤后应激障碍（PTSD）的主要资产TN-001，它是一种双重5-HT

partial agonist/5-HT

部分激动剂/5-HT

antagonist with serotonergic receptor engagement tailored to deliver rapid and enduring antidepressant efficacy rivaling psychedelic treatment, but without hallucinations or dissociative effects.

与血清素受体结合的拮抗剂，旨在提供快速且持久的抗抑郁效果，媲美迷幻治疗，但不会产生幻觉或解离效应。

Media Contact

媒体联系人

Liz Cogan

丽兹·科根

media@transneural.com

媒体@跨神经网络.com

+1.619.780.7684

SOURCE Transneural Therapeutics, Inc.

源代码：跨神经治疗公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻